BN ImmunoTherapeutics Updates On Phase I/II Studies With Breast Cancer Vaccine

News — By on February 24, 2009 at 3:00 am

BN ImmunoTherapeutics, Inc. provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2. The study met its primary endpoint with regards to safety and by showing an immune response. Evidence of vaccine-induced anti-HER2 immune response was detected in approximately 70% of evaluated patients.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback